Date: 2016-12-01
Type of information: Nomination
Compound:
Company: Aimmune Therapeutics (USA - CA) previously Allergen Research Corporation (ARC)
Therapeutic area: Allergic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On December 1, 2016, Aimmune Therapeutics announced the membership of its Scientific Advisory Board, comprised of internationally recognized food allergy experts. The Scientific Advisory Board members and their academic affiliations are:
- - Dr. Kirsten Beyer, Professor in the Department of Pediatric Pneumology and Immunology at University Hospital Charité in Berlin. Her research experience spans the spectrum of pediatric allergy, with a focus on food allergy. Her interests include food allergy prevention, diagnosis and treatment. Currently, her group is studying the induction of oral tolerance through oral immunotherapy in food-allergic children and the primary prevention of hen’s egg allergy through early hen’s egg feeding, among other studies. She is also part of the EU-funded food allergy project EuroPrevall, studying a European birth cohort of more than 12,000 babies, which will be re-evaluated at school age within the EU-funded project iFAAM.
- - Dr. A. Wesley Burks, Executive Dean for the University of North Carolina School of Medicine as well as the Curnen Distinguished Professor in the Department of Pediatrics. Dr. Burks heads a research team whose work centers on the molecular identification of the allergens in specific foods, a better understanding of the mechanism of adverse food reactions, and the development of treatment for food allergy in pre-clinical and clinical studies. He and his colleagues have several ongoing clinical studies with different types of mucosal immunotherapy. Dr. Burks is also a principal investigator for the Consortium of Food Allergy Research (CoFAR), which was established in July 2005 by the National Institute of Allergy and Infectious Diseases (NIAID) to conduct both observational and clinical studies to answer questions related to food allergies.
- - Dr. Thomas Casale, Professor of Medicine and Pediatrics at the College of Medicine at the University of South Florida in Tampa, Florida. Dr. Casale's clinical and basic research interests are directed toward determination and treatment of the pathophysiologic mechanisms involved in asthma and allergic diseases. He is currently the director of clinical and translational research and is actively involved in examining immunomodulators for the treatment of inflammatory disorders. He is also very active in the development of educational programs in allergy and immunology for local, national and international meetings. He served as President of the American Academy of Allergy, Asthma and Immunology from 2007 to 2008.
- - Dr. Jonathan Hourihane, Professor of Paediatrics and Child Health at University College Cork in Ireland. His research interests focus on the exploration of the link between skin barrier dysfunction and systemic allergic disorders, threshold doses of food allergens, immunomodulation of established allergic responses, prevention of allergic sensitization, and evaluation of quality of life in food allergic children. He is co-principal investigator for the BASELINE birth cohort study, which is tracking more than 2,000 Irish children from soon after conception over several years to study the effects of intrauterine growth restriction, the incidence and prevalence of food allergy and eczema in early childhood, and the incidence and effects of maternal and infant vitamin D status on growth and health. He was Founding Secretary of the Irish Association of Allergy and Immunology and is Founding Chairman of the Irish Food Allergy Network.
- - Dr. Stacie Jones, Professor of Pediatrics and Chief of Allergy and Immunology at the University of Arkansas for Medical Sciences and Arkansas Children's Hospital. She is also a researcher at the Arkansas Children's Research Institute. Her research focuses on both clinical and translational investigation of food allergy and eosinophilic gastrointestinal disorders, as well as on asthma and lung disease. Dr. Jones is also a principal investigator for the Consortium of Food Allergy Research (CoFAR).
- All of the members of Aimmune’s Scientific Advisory Board are investigators in PALISADE, Aimmune’s current Phase 3 clinical trial of AR101 for the treatment of peanut allergy.
Financial terms:
Latest news:
Is general: Yes
